

**Freedom of Information Act 2000 – Request Reference FoI/24/379**  
**Intravitreal Treatments**

**For the 4 months from January to April 2024, how many patients received the following intra-vitreous treatments for any eye condition:**

Below is the data for the number of patients who received the following intravitreal treatments for any eye condition from 1 January 2024 to 30 April 2024.

- Aflibercept (Eylea) – 1,781
- Bevacizumab – 0
- Brolucizumab – 0
- Dexamethasone (Ozurdex) – 46
- Faricimab (Vabysmo) – 413
- Ranibizumab (Lucentis) – 13
- Ranibizumab (Ongavia) – 462